NeurAxis Highlights Strength of its Board of Directors
CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
- CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
- “We are fortunate to have a board with a depth of experience in relevant areas to NeurAxis, including medical device commercialization, commercial insurance, and finance.
- “We are excited to have this strength at the board level as we continue to develop and drive adoption of our IB Stim Therapy™,” concluded Mr. Carrico.
- The Company’s Board of Directors includes:
Ms. Keyser has more than 20 years of experience in executive roles in population health.